333例proGAV®与proGAV 2.0®可调压阀在小儿脑积水治疗中的对比分析:生存率与并发症率评估
本回顾性研究纳入2008年8月至2020年8月在本神经外科诊所接受ProGAV或ProGAV2.0阀植入的全部小儿患者,比较两种阀的生存率与并发症率。共333例,ProGAV组173例(52.0%),ProGAV2.0组160例(48.0%),随访最长3年。ProGAV2.0在并发症率和调节困难率方面表现更优,两种阀三年生存率分别为65.3%和71.3%。
要点
- ProGAV2.0组早期并发症率22% vs ProGAV组9.4%,p=0.002。
- ProGAV2.0组调节困难与自发调节关联显著更高(p=0.041和0.011)。
- 小于2岁患儿调节困难显著更多(p=0.049),阀取出率更高(p<0.001)。
核心结论
- ProGAV2.0阀在小儿脑积水治疗中并发症率和调节不当率方面表现优于ProGAV阀。
- 两种阀三年内生存率分别为ProGAV 65.3%和ProGAV2.0 71.3%,均可接受。
研究设计与样本
- 回顾性研究,纳入2008年8月至2020年8月在本神经外科诊所接受ProGAV或ProGAV2.0阀植入的全部小儿患者。
- 共333例,平均年龄5.4±5.1岁,男性54.1%;ProGAV组173例(52.0%),ProGAV2.0组160例(48.0%)。
- 所有阀随访最长3年。
主要发现
- 植入后第一个月内早期并发症51例(15.3%)。
- 两组阀植入指征、年龄分布及生存时间(27.1 vs 27.8个月,p=0.629)无显著差异。
- 两组主要植入指征均为出血后脑积水和导水管狭窄。
- 植入后前三年取出率两组无显著差异(34.7% vs 29.7%,p<0.289)。
- ProGAV2.0组早期并发症率显著更高(22% vs 9.4%,p=0.002),调节困难与自发调节关联显著更高(p=0.041和0.011)。
临床怎么用
- 作者认为ProGAV2.0阀在小儿脑积水治疗中并发症率和调节不当率方面表现更优。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: ProGAV and ProGAV2.0 adjustable valves are extensively used for treating hydrocephalus in pediatric patients. This study aims to conduct a comprehensive comparison between these two valves concerning their survival and complication rates. METHODS: This retrospective study included all pediatric patients who underwent ProGAV or ProGAV2.0 valve implantation at our neurosurgical clinic from August 2008 to August 2020. A comparative analysis was performed considering age, gender, follow-up duration, complication and survival rates, adjustments, spontaneous adjustments, and adjustment difficulty rates. All valves were followed up for a maximum of 3 years. RESULTS: Inclusion involved 333 cases (mean age of 5.4 ± 5.1 years; 54.1% males), comprising 173 cases (52.0%) with ProGAV valve implantation and 160 cases (48.0%) with ProGAV 2.0. Early complications within the first month post-implantation were observed in 51 cases (15.3%). No significant differences were noted in valve implantation indications, age distribution, or survival duration (27.1 vs. 27.8 months, p = 0.629) between the two groups. Predominant indications for implantation were post-hemorrhagic hydrocephalus and aqueduct stenosis for both valve types. Notably, both valves showed non-significantly different explantation rates during the first three years after implantation (34.7% vs. 29.7%, p < 0.289). However, there was a significantly higher early post-implantation complication rate (22% vs. 9.4%, p = 0.002), and a significantly increased association with difficulties in valve adjustments and spontaneous adjustments (p = 0.041 and 0.011, respectively). ProGAV2.0 cases displayed notably enhanced clinical and radiological improvement within the initial 6 months after implantation (p = 0.001 and p = 0.038). Younger children (< 2 years of age) also experienced significantly more valve adjustment difficulties (p = 0.049) and had higher rates of valve explantation (p < 0.001). CONCLUSION: The findings of this study highlight the superior performance of the ProGAV2.0 valve in terms of complication rate and maladjustment rate when employed in the treatment of pediatric hydrocephalus. Both valves demonstrated an acceptable survival rate with 65.3% for ProGAV and 71.3% for ProGAV2.0 within three years of implantation.
引用
- Issa M, Paggetti F, Dannehl C, et al. Comparative analysis of 333 proGAV® and proGAV 2.0® adjustable valves in pediatric hydrocephalus treatment: survival and complication rate assessment. Acta Neurochir (Wien). 2024. PMID: 39520603. doi:10.1007/s00701-024-06348-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。